2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1370

Development and Validation of a Composite Disease Activity Score for Juvenile Dermatomyositis

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 1298

Development and Validation of Berlin and Sparcc MRI Sacroiliac Joint Scoring Methods for the Semi-Axial Scan Plan

Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

9:00AM-11:00AM: Abstract Number: 1945

Development and Validation of Case-Finding Algorithms for the Identification of Patients with ANCA-Associated Vasculitis and Large-Vessel Vasculitis in Healthcare Administrative Databases

Vasculitis - Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1160

Development of a Shared Decision Making Tool for Osteoporosis Treatment

Education - ARHP Poster

9:00AM-11:00AM: Abstract Number: 1156

Development of a Taxonomy of Patient Engagement in Health Research

Education - ARHP Poster

9:00AM-11:00AM: Abstract Number: 1247

Diagnostic Modeling of Rheumatoid Arthritis in Oklahoma Tribal Members Using Soluble Mediators

Healthcare Disparities in Rheumatology - Poster II

9:00AM-11:00AM: Abstract Number: 1667

Diagnostic Value of Anti-CD74 Antibodies in Axial Spondyloarthritis: Results from a Population with Low HLA-B27 Prevalence Background

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster I

9:00AM-11:00AM: Abstract Number: 1476

Diastolic Dysfunction in Patients with Rheumatoid Arthritis: Predictors of Longitudinal Progression over Five Years

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1778

Differences Between Early and Late Cardiovascular Disease in a Population-Based Cohort of Systemic Lupus Erythematosus Patients

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1444

Differential Expression of Wnt Inhibitors before and after Joint Inflammation Onset in Rat Arthritis Could Partly Explain Paradoxical Effect of Sclerostin Inhibition

Rheumatoid Arthritis – Animal Models - Poster II

9:00AM-11:00AM: Abstract Number: 1219

Differential Peripheral Blood DNA Methylation Patterns Are Predictive of Radiographic OA Progression

Genetics, Genomics and Proteomics - Poster II

9:00AM-11:00AM: Abstract Number: 1654

Differential Serum Protein Expression in Groups of Psoriatic Arthritis Patients Characterised By Specific HLA Genotypes and Clinical Features

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster I

9:00AM-11:00AM: Abstract Number: 1203

Differential Synovial Expression Patterns in Early Osteoarthritis Predict Pain and Progression of Joint Damage

Genetics, Genomics and Proteomics - Poster II

9:00AM-11:00AM: Abstract Number: 1102

Differentiation of Spongiosa-Derived Mesenchymal Stromal Cells from Osteoporosis and Osteoarthritis Patients Are Influenced By Adipokines

Biology and Pathology of Bone and Joint - Poster II

9:00AM-11:00AM: Abstract Number: 1360

Discontinuation Causes of Biological Therapies: Over a Five-Year Period. Biobadasar

Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].